🇺🇸 FDA
Pipeline program

NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

CABL001J12302

Phase 3 small_molecule active

Quick answer

NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB for Chronic Myeloid Leukemia is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Chronic Myeloid Leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials